Evoke Pharma Inc (EVOK)

Currency in USD
11.0000
0.0000(0.00%)
Closed·
Showing Evoke Pharma historical data. For real-time data please try another search
Fair Value
Day's Range
10.980011.0000
52 wk Range
1.940011.0000
Key Statistics
Prev. Close
11
Open
10.98
Day's Range
10.98-11
52 wk Range
1.94-11
Volume
-
Average Volume (3m)
105.81K
1-Year Change
121.7742%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EVOK Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.0000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Evoke Pharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.0000
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Evoke Pharma Inc Earnings Call Summary for H2/2025

  • Evoke Group reported 2% revenue growth to £1.8B and 14% adjusted EBITDA increase to £356M, with leverage ratio improving from 5.7x to 5.2x
  • UK duty changes created significant headwinds; company targeting at least 50% mitigation in first year with EPS forecast at $0.15 for FY2025
  • International markets, particularly Italy and Denmark, drove growth offsetting domestic UK challenges and retail sector weakness
  • EBITDA margin expanded 220 basis points to 20% through operational efficiencies; underlying free cash flow reached £188M despite pressures
  • Romanian market faced dual challenges from tax changes and recession, while black market competition impacted regulated operators' performance
Last Updated: 2026/04/30, 10:46
Read Full Transcript

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0,45 / --
Revenue / Forecast
4,28M / 4,28M
EPS Revisions
Last 90 days

EVOK Income Statement

Compare EVOK to Peers and Sector

Metrics to compare
EVOK
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x2.6x
Price / LTM Sales
0.0x0.0x3.2x
Upside (Analyst Target)
0.0%0.0%48.1%
Fair Value Upside
Unlock0.0%6.6%Unlock

Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California. As of December 15, 2025, Evoke Pharma, Inc. operates as a subsidiary of QOL Medical, LLC.

Employees
3
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.